Literature DB >> 11336691

Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

A Le Bon1, G Schiavoni, G D'Agostino, I Gresser, F Belardelli, D F Tough.   

Abstract

Type I interferons (IFN-I) are rapidly induced following infection and play a key role in nonspecific inhibition of virus replication. Here we have investigated the effects of IFN-I on the generation of antigen-specific antibody responses. The data show that IFN-I potently enhance the primary antibody response to a soluble protein, stimulating the production of all subclasses of IgG, and induce long-lived antibody production and immunological memory. In addition, endogenous production of IFN-I was shown to be essential for the adjuvant activity of CFA. Finally, IFN-I enhanced the antibody response and induced isotype switching when dendritic cells were the only cell type responding to IFN-I. The data reveal the potent adjuvant activity of IFN-I and their important role in linking innate and adaptive immunity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11336691     DOI: 10.1016/s1074-7613(01)00126-1

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  332 in total

Review 1.  IFNs and STATs in innate immunity to microorganisms.

Authors:  Thomas Decker; Silvia Stockinger; Marina Karaghiosoff; Mathias Müller; Pavel Kovarik
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  T-bet regulates IgG class switching and pathogenic autoantibody production.

Authors:  Stanford L Peng; Susanne J Szabo; Laurie H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

3.  Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.

Authors:  Uma Sriram; Linda Varghese; Heather L Bennett; Neelakshi R Jog; Debra K Shivers; Yue Ning; Edward M Behrens; Roberto Caricchio; Stefania Gallucci
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

4.  Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus.

Authors:  Yuan Fang; Thomas Rowe; Alberto J Leon; David Banner; Ali Danesh; Luoling Xu; Longsi Ran; Steven E Bosinger; Yi Guan; Honglin Chen; Cheryl C Cameron; Mark J Cameron; David J Kelvin
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

5.  Clinical reagents of GM-CSF and IFN-α induce the generation of functional chronic myeloid leukemia dendritic cells in vitro.

Authors:  Kaizhi Weng; Xiaobao Xie; Guoqiang Qiu; Weiying Gu
Journal:  Cytotechnology       Date:  2011-09-22       Impact factor: 2.058

Review 6.  Influenza vaccines: present and future.

Authors:  Peter Palese; Adolfo García-Sastre
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

7.  Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.

Authors:  Akram Abouie Mehrizi; Niloufar Rezvani; Sedigheh Zakeri; Atefeh Gholami; Laleh Babaeekhou
Journal:  Med Microbiol Immunol       Date:  2018-02-03       Impact factor: 3.402

8.  Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus.

Authors:  C R Baskin; H Bielefeldt-Ohmann; A García-Sastre; T M Tumpey; N Van Hoeven; V S Carter; M J Thomas; S Proll; A Solórzano; R Billharz; J L Fornek; S Thomas; C-H Chen; E A Clark; Kaja Murali-Krishna; M G Katze
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  Interferon gamma modulation of disease manifestation and the local antibody response to alphavirus encephalomyelitis.

Authors:  Victoria K Baxter; Diane E Griffin
Journal:  J Gen Virol       Date:  2016-09-22       Impact factor: 3.891

Review 10.  Extracellular DNA and autoimmune diseases.

Authors:  Hantao Lou; Matthew C Pickering
Journal:  Cell Mol Immunol       Date:  2018-03-19       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.